Neuroretinal dysfunction in patients affected by neurofibromatosis type 1

AIM: To examine neuroretinal function by using the multifocal electroretinography (mfERG) test in patients with neurofibromatosis type 1 (NF1) without optic pathway gliomas (OPGs). METHODS: This study was conducted on 35 patients (35 eyes) with NF1 and 30 healthy subjects (30 eyes) for the control g...

Full description

Bibliographic Details
Main Authors: Antonietta Moramarco, Luca Lucchino, Fabiana Mallone, Michela Marcelli, Ludovico Alisi, Vincenzo Roberti, Sandra Giustini, Alessandro Lambiase, Marcella Nebbioso
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2022-05-01
Series:International Journal of Ophthalmology
Subjects:
Online Access:http://ies.ijo.cn/en_publish/2022/5/20220513.pdf
_version_ 1828491832059756544
author Antonietta Moramarco
Luca Lucchino
Fabiana Mallone
Michela Marcelli
Ludovico Alisi
Vincenzo Roberti
Sandra Giustini
Alessandro Lambiase
Marcella Nebbioso
author_facet Antonietta Moramarco
Luca Lucchino
Fabiana Mallone
Michela Marcelli
Ludovico Alisi
Vincenzo Roberti
Sandra Giustini
Alessandro Lambiase
Marcella Nebbioso
author_sort Antonietta Moramarco
collection DOAJ
description AIM: To examine neuroretinal function by using the multifocal electroretinography (mfERG) test in patients with neurofibromatosis type 1 (NF1) without optic pathway gliomas (OPGs). METHODS: This study was conducted on 35 patients (35 eyes) with NF1 and 30 healthy subjects (30 eyes) for the control group. Each subject underwent a complete ophthalmological examination including spectral domain-optical coherence tomography (SD-OCT) and mfERG. The 1.5-Tesla magnetic resonance imaging (MRI) scan of the brain was performed in NF1 patients to assess the presence of OPGs. All participants were recruited having a best corrected visual acuity (BCVA) of no less than 20/20 in each eye. The amplitude and implicit time of the P1 wave (first-order Kernel component) were evaluated on mfERG. Data analysis was carried out in the two central degrees and in the four quadrants from two to 25 degrees of visual field. RESULTS: Statistically significant results were obtained for the P1 wave amplitudes in the 4 quadrants in NF1 patients compared to healthy controls, while the reduction was not significant in the 2 central degrees between the groups. A statistically significant difference was observed among the P1 wave amplitudes as recorded in the 4 quadrants within the NF1 group, with lower amplitudes detected in the nasal quadrants. No differences in the implicit times were recorded in the 2 central degrees and in the 4 quadrants as compared between NF1 patients and controls. CONCLUSION: Impaired neuroretinal function in NF1 patients is expressed in a decreased amplitude of the P1-wave between 2 and 25 central retinal degrees on mfERG. Altered intracellular signal transduction due to abnormal neurofibromin-mediated cyclic adenosine monophosphate (cAMP) generation, can be involved. The possible use of mfERG as subclinical retinal damage indicator has a potential utility in clinical practice for the follow-up of NF1 patients.
first_indexed 2024-12-11T11:09:42Z
format Article
id doaj.art-18b81dfe1e4e440ebb4b73a75702903e
institution Directory Open Access Journal
issn 2222-3959
2227-4898
language English
last_indexed 2024-12-11T11:09:42Z
publishDate 2022-05-01
publisher Press of International Journal of Ophthalmology (IJO PRESS)
record_format Article
series International Journal of Ophthalmology
spelling doaj.art-18b81dfe1e4e440ebb4b73a75702903e2022-12-22T01:09:35ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982022-05-0115577377910.18240/ijo.2022.05.1320220513Neuroretinal dysfunction in patients affected by neurofibromatosis type 1Antonietta Moramarco0Luca Lucchino1Fabiana Mallone2Michela Marcelli3Ludovico Alisi4Vincenzo Roberti5Sandra Giustini6Alessandro Lambiase7Marcella Nebbioso8Alessandro Lambiase. Ophthalmology at Department of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, Rome 00161, Italy. Alessandro.lambiase@uniroma1.itDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, ItalyAIM: To examine neuroretinal function by using the multifocal electroretinography (mfERG) test in patients with neurofibromatosis type 1 (NF1) without optic pathway gliomas (OPGs). METHODS: This study was conducted on 35 patients (35 eyes) with NF1 and 30 healthy subjects (30 eyes) for the control group. Each subject underwent a complete ophthalmological examination including spectral domain-optical coherence tomography (SD-OCT) and mfERG. The 1.5-Tesla magnetic resonance imaging (MRI) scan of the brain was performed in NF1 patients to assess the presence of OPGs. All participants were recruited having a best corrected visual acuity (BCVA) of no less than 20/20 in each eye. The amplitude and implicit time of the P1 wave (first-order Kernel component) were evaluated on mfERG. Data analysis was carried out in the two central degrees and in the four quadrants from two to 25 degrees of visual field. RESULTS: Statistically significant results were obtained for the P1 wave amplitudes in the 4 quadrants in NF1 patients compared to healthy controls, while the reduction was not significant in the 2 central degrees between the groups. A statistically significant difference was observed among the P1 wave amplitudes as recorded in the 4 quadrants within the NF1 group, with lower amplitudes detected in the nasal quadrants. No differences in the implicit times were recorded in the 2 central degrees and in the 4 quadrants as compared between NF1 patients and controls. CONCLUSION: Impaired neuroretinal function in NF1 patients is expressed in a decreased amplitude of the P1-wave between 2 and 25 central retinal degrees on mfERG. Altered intracellular signal transduction due to abnormal neurofibromin-mediated cyclic adenosine monophosphate (cAMP) generation, can be involved. The possible use of mfERG as subclinical retinal damage indicator has a potential utility in clinical practice for the follow-up of NF1 patients.http://ies.ijo.cn/en_publish/2022/5/20220513.pdfneurofibromatosis type 1multifocal electroretinographyneuroretinal functionoptic pathway gliomasneurofibromin
spellingShingle Antonietta Moramarco
Luca Lucchino
Fabiana Mallone
Michela Marcelli
Ludovico Alisi
Vincenzo Roberti
Sandra Giustini
Alessandro Lambiase
Marcella Nebbioso
Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
International Journal of Ophthalmology
neurofibromatosis type 1
multifocal electroretinography
neuroretinal function
optic pathway gliomas
neurofibromin
title Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
title_full Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
title_fullStr Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
title_full_unstemmed Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
title_short Neuroretinal dysfunction in patients affected by neurofibromatosis type 1
title_sort neuroretinal dysfunction in patients affected by neurofibromatosis type 1
topic neurofibromatosis type 1
multifocal electroretinography
neuroretinal function
optic pathway gliomas
neurofibromin
url http://ies.ijo.cn/en_publish/2022/5/20220513.pdf
work_keys_str_mv AT antoniettamoramarco neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT lucalucchino neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT fabianamallone neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT michelamarcelli neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT ludovicoalisi neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT vincenzoroberti neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT sandragiustini neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT alessandrolambiase neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1
AT marcellanebbioso neuroretinaldysfunctioninpatientsaffectedbyneurofibromatosistype1